Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) has earned a consensus rating of “Moderate Buy” from the five analysts that are currently covering the stock, MarketBeat reports. Two analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $38.00.

A number of equities analysts recently weighed in on INO shares. Royal Bank of Canada reduced their target price on shares of Inovio Pharmaceuticals from $7.00 to $6.00 and set a “sector perform” rating for the company in a research note on Friday, November 15th. Oppenheimer reduced their price objective on Inovio Pharmaceuticals from $33.00 to $15.00 and set an “outperform” rating for the company in a research report on Monday, November 18th. Finally, HC Wainwright dropped their target price on Inovio Pharmaceuticals from $12.00 to $5.00 and set a “neutral” rating on the stock in a research report on Monday, November 18th.

Institutional Investors Weigh In On Inovio Pharmaceuticals

Large investors have recently made changes to their positions in the stock. Bank of New York Mellon Corp bought a new position in Inovio Pharmaceuticals during the second quarter worth about $661,000. Dimensional Fund Advisors LP bought a new position in shares of Inovio Pharmaceuticals during the 2nd quarter worth approximately $605,000. Wellington Management Group LLP acquired a new position in shares of Inovio Pharmaceuticals during the 3rd quarter worth approximately $379,000. State Street Corp raised its stake in Inovio Pharmaceuticals by 11.7% in the 3rd quarter. State Street Corp now owns 490,662 shares of the biopharmaceutical company’s stock valued at $2,836,000 after acquiring an additional 51,414 shares during the period. Finally, Geode Capital Management LLC lifted its holdings in Inovio Pharmaceuticals by 6.7% during the 3rd quarter. Geode Capital Management LLC now owns 621,631 shares of the biopharmaceutical company’s stock valued at $3,594,000 after purchasing an additional 38,833 shares during the last quarter. Institutional investors and hedge funds own 26.79% of the company’s stock.

Inovio Pharmaceuticals Stock Performance

Shares of INO opened at $4.03 on Thursday. Inovio Pharmaceuticals has a twelve month low of $3.85 and a twelve month high of $14.75. The firm’s 50 day moving average price is $4.99 and its two-hundred day moving average price is $7.23. The firm has a market cap of $105.05 million, a P/E ratio of -1.16 and a beta of 0.75.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.